Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)Simon J. Crabb, Robert J. Jones, Michelle Light et al.|Journal of Clinical Oncology|2020Cited by 82
Expert survey on management of prostate cancer in IndiaGanesh Bakshi, Vedang Murthy, Hemant Tongaonkar et al.|Indian Journal of Cancer|2022Cited by 10
ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC).Simon J. Crabb, Robert J. Jones, Gareth Griffiths et al.|Journal of Clinical Oncology|2020Cited by 2